# Anti-Migraine Agents, Acute

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred     | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Naratriptan   |              |          |             |
| Nurtec ODT ST |              |          |             |
| Rizatriptan   |              |          |             |
| Sumatriptan   |              |          |             |

### Non-Preferred

| Non-Preferred        | Generic Name | Quantity | Time (Days) |
| :------------------- | :----------- | :------: | :---------: |
| Almotriptan          |              |          |             |
| Dihydroergotamine    |              |          |             |
| Eletriptan           |              |          |             |
| Ergomar              |              |          |             |
| Frovatriptan         |              |          |             |
| Migergot             |              |          |             |
| Onzetra Xsail        |              |          |             |
| Reyvow               |              |          |             |
| Sumatriptan/Naproxen |              |          |             |
| Tosymra              |              |          |             |
| Trudhesa             |              |          |             |
| Ubrelvy              |              |          |             |
| Zolmitriptan         |              |          |             |

## Length of Authorizations

180 Days

## Prior Authorization Criteria

- Is there any reason the patient cannot be changed to a medication not requiring prior approval?

  Acceptable reasons include:

  - Allergy to preferred medications
  - Contraindication to all preferred medications
  - History of unacceptable/toxic side effects to at least two preferred medications

## Additional Criteria

### Step Therapy

Step Therapy Approval Criteria

- For a drug requiring step therapy, there must have been inadequate clinical response to preferred alternatives, including a trial of at least 14 days with at least two medications not requiring prior approval
- For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of at least 14 days with at least one medication requiring step therapy

Nurtec ODT quantity limit is 8 per 30 days

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=23)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=13)
